Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 13/20 | 0.36 |
| ▸ | CYP1A1 | P04798 | 1/20 | 0.34 |
| ▸ | CYP1B1 | Q16678 | 1/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.31 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
| ▸ | PREP | P48147 | 1/20 | 0.30 |
| ▸ | DPP9 | Q86TI2 | 1/20 | 0.30 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16738523 | 0.85 | ALDH1A1 (0.35) | NPC1RAB9A | |
| SCHEMBL1219449 | 0.81 | GABRA1 (0.47) | HPGDTSHRNPC1RAB9A | |
| SCHEMBL6373525 | 0.68 | ERN1 (0.39) | CA2 | |
| SCHEMBL2477598 | 0.67 | CA1 (0.48) | HPGDTSHRHSD17B10DPP4CA2 | |
| SCHEMBL2477599 | 0.67 | CA1 (0.48) | HPGDTSHRHSD17B10DPP4CA2 | |
| SCHEMBL27976640 | 0.67 | EGFR (0.53) | HPGDTSHRHSD17B10DPP4CA2 | |
| SCHEMBL3377931 | 0.67 | ERN1 (0.54) | HPGDTSHRHSD17B10NPC1RAB9A | |
| SCHEMBL13303891 | 0.66 | DPP4 (0.42) | HPGDHSD17B10DPP4CYP1A1CYP1B1 | |
| SCHEMBL16738481 | 0.66 | HSP90AA1 (0.41) | HPGDTSHRHSD17B10CA2CA1 | |
| SCHEMBL10884046 | 0.65 | AKR1C3 (0.44) | TSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | ARDELYX INC (US) | 2015-05-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150148311-A1 | NON-SYSTEMIC TGR5 AGONISTS | GLP1R, GPR119, TRHR | HPGD 4508/4885TSHR 6/4885HSD17B10 3131/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.